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Introduction: The reported incidence of ventilator-associated pneumonia (VAP) inWales
is low compared with surveillance data from other European regions. It is unclear whether
this reflects success of the Welsh healthcare-associated infection prevention measures
or limitations in the application of European VAP surveillance methods. Our primary aim
was to investigate episodes of ventilator-associated respiratory tract infection (VARTI),
to identify episodes that met established criteria for VAP, and to explore reasons why
others did not, according to the Hospitals in Europe Link for Infection Control through
Surveillance (HELICS) definitions.
Materials and Methods: During two 14-day study periods 2012–2014, investigators
reviewed all invasively ventilated patients in all 14 Welsh Intensive Care Units (ICUs).
Episodes were identified in which the clinical team had commenced antibiotic therapy
because of suspected VARTI. Probability of pneumonia was estimated using a modified
Clinical Pulmonary Infection Score (mCPIS). Episodes meeting HELICS definitions of VAP
were identified, and reasons for other episodes not meeting definitions examined. In the
second period, each patient was also assessed with regards to the development of a
ventilator-associated event (VAE), according to recent US definitions.
Results: The study included 306 invasively ventilated patients; 282 were admitted
to ICU for 48 h or more. 32 (11.3%) patients were commenced on antibiotics
for suspected VARTI. Ten of these episodes met HELICS definitions of VAP, an
incidence of 4.2 per 1000 intubation days. In 48% VARTI episodes, concurrent
chest radiography was not performed, precluding the diagnosis of VAP. Mechanical
ventilation (16.0 vs. 8.0 days; p = 0.01) and ICU stay (25.0 vs. 11.0 days;
p = 0.01) were significantly longer in patients treated for VARTI compared to
those not treated. There was no overlap between episodes of VARTI and of VAE.
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Discussion: HELICS VAP surveillance definitions identified less than one-third of cases
in which antibiotics were commenced for suspected ventilator-associated RTI. Lack of
chest radiography precluded nearly 50% cases from meeting the surveillance definition
of VAP, and as a consequence we are almost certainly underestimating the incidence of
VAP in Wales.
Keywords: ventilator-associated pneumonia, ventilator-associated tracheobronchitis, respiratory tract infection,
ventilator-associated event, ventilator-associated complication, surveillance
INTRODUCTION
Pneumonia is the major cause of ICU-acquired infection in
Europe and the United States (Vincent et al., 1995; Richards
et al., 2000; Burgmann et al., 2010), the vast majority of episodes
occurring in intubated and mechanically-ventilated patients
(ventilator-associated pneumonia, VAP; Kohlenberg et al., 2010).
VAP tends to occur in the sickest of critically ill patients (Chastre
and Fagon, 2002; Blot et al., 2014) and is associated with
appreciable morbidity, mortality, and financial cost (Safdar et al.,
2005; Bekaert et al., 2011; Melsen et al., 2013; Muscedere et al.,
2013). Given that some factors associated with development of
VAP appear modifiable (Barbier et al., 2013), attention has been
focused on regional and national healthcare-associated infection
(HAI) surveillance indices to guide local quality improvement
and wider bench-marking.
The Welsh Healthcare-Associated Infection Programme
(WHAIP) has monitored episodes of VAP through the National
Mandatory Healthcare Associated Infection Surveillance
Programme for Wales since 2008. Using European HELICS
surveillance definitions (Table 1; HELICS, 2004) clinical staff in
each ICU have reported VAP episodes equivalent to an incidence
density of 1.2–2.2 per 1000 intubation days for 2009–2013
(WHAIP, 2014). These rates are low when compared to data
from other areas of the UK (Scotland, 6.5 per 1000 intubation
days; HPS/SICSAG, 2013) and Europe (12.2 per 1000 intubation
days; ECDC, 2008). This may reflect the success of national
healthcare improvement initiatives in Wales (e.g., the 1000
Lives Campaign), but could feasibly underestimate the true
incidence of ventilator-associated pneumonia (VAP) given how
subjective the clinical and radiological features of VAP can
be (Klompas, 2012). In the US, loss of confidence has led to
the recent revision of ICU surveillance methodology and the
introduction of alternate ventilator-associated event (VAE)
surveillance definitions by the Centers for Disease Control and
Prevention National Healthcare Safety Network (CDC NHSN).
The primary focus of these definitions is now an objective
deterioration in oxygenation (Figure 1; Magill et al., 2013).
Such “Ventilator-Associated Conditions” (VACs) may then
potentially be sub-classified according to other unambiguous
features (temperature, white cell count, and initiation of
antibiotic therapy) as an Infection-related Ventilator-Associated
Complication (I-VAC) for mandatory surveillance purposes.
Our primary aim was to identify episodes of VAP according to
theHELICS definition, and to explore reasons why other episodes
of ventilator-associated respiratory tract infection (VARTI) did
not meet the criteria. Our secondary aims were to investigate
clinical outcomes among the wider group of patients being
treated for suspected VARTI, and to explore the feasibility
of using alternative methods to identify infective ventilator-
associated morbidity for surveillance purposes in Wales.
MATERIALS AND METHODS
A prospective evaluation of current clinical practice by individual
Health Boards was conducted within the mandated critical
care surveillance programme in Wales. For this reason formal
ethical approval was not necessary, however the Clinical Audit
departments at each center approved participation.
The study was conducted in two stages. During the initial
14-day study period (November 2012), local investigators
identified through the Welsh Intensive Care Society Audit
and Research Group (WICSARG) were asked to complete
a daily standard data collection form for each intubated
and mechanically ventilated patient either already present
on or admitted to their ICU. A VARTI was considered
to have occurred when the clinical team commenced an
invasively ventilated patient on systemic antibiotic therapy
for suspected respiratory infection 48 h or more after ICU
admission. For each episode, clinical and radiological features
were recorded in order to make a diagnosis of pneumonia
TABLE 1 | HELICS case definition of intubation-associated pneumonia
(HELICS, 2004).
Criteria Feature
Radiological. One or, in patients with underlying cardiac or pulmonary disease,
two chest x-rays or CT scans with image suggestive of pneumonia
Systemic. At least one of: 1. Fever (>38◦C)
2. Leukopenia (<4 × 109/L white blood
cells) or leukocytosis (≥12 × 109/L
white blood cells)
Pulmonary. At least one of, or in the
absence of supportive microbiological
data, at least two of:
1. New onset of purulent sputum, or
change in character of sputum
2. Worsening gas exchange
3. Cough, or dyspnoea, or tachypnoea
4. Suggestive auscultation
An ICU-acquired infection is one which occurs later than 48 h in ICU. Patients must fulfill
radiological, systemic and pulmonary criteria to meet the HELICS definition of pneumonia.
For Intubation-associated pneumonia, an invasive respiratory device must have been
present for at least part of the preceding 48 h.
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FIGURE 1 | Ventilator-associated events surveillance algorithm. Adapted from Magill (Klompas, 2012).
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according to the HELICS definition (Table 1). The modified
Clinical Pulmonary Infection Score (mCPIS) was also calculated
(Table 2; Fartoukh et al., 2003) and used to give an indication
of likelihood of pneumonia, with a score of 6 or more
interpreted as suggesting a high probability. Microbiology
results from contemporaneous respiratory specimens were also
collected.
The second stage of the study was undertaken between
March and April 2014. During this period, ventilator settings
TABLE 2 | Modified clinical pulmonary score (mCPIS; Fartoukh et al.,
2003).
Component Value Points
Temperature (◦C) ≥36.5 and ≤38.4 0
≥38.5 and ≤39.0, or ≥36.1 and ≤36.4 1
≤36.0 or ≥39.0 2
Blood leukocytes (×109/L) ≥4 and ≤11 0
<4 or >11 1
Tracheal secretions Rare 0
Abundant 1
Abundant and purulent 2
Oxygenation PaO2:FiO2 > 31.6 kPa 0
PaO2:FiO2 ≤ 31.6 kPa 2
Chest radiograph No infiltrate 0
Patchy or diffuse infiltrate 1
Localized infiltrate 2
Total
Modified CPIS of six or more considered to represent a high probability of pneumonia.
and physiological measurements were also collected daily to
enable additional identification of VAE according to NHSN CDC
definitions, (see Figure 1; Magill et al., 2013). Episodes of VARTI
and VAP according to the HELICS definition were identified as
previously. For this stage of the study, investigators were also
asked to submit 90-day outcome data (duration of mechanical
ventilation and ICU length of stay, ICU, and hospital mortality)
from their local WardWatcher (Critical Care Audit Ltd., UK)
database.
STATISTICAL ANALYSIS
Our primary outcomes were: episodes of VARTI (as defined
above) and of VAP, according to the HELICS definition.
Secondary outcomes were: probability of pneumonia in all cases
of VARTI according to a mCPIS, and episodes of VAE and 90-
day outcomes (for patients in the second stage of the study).
Data was collected using Microsoft Access and analyzed using
MINITAB 13.32 (Minitab Inc., UK). T-tests were used to analyze
normally-distributed data and Mann–Whitney U-test for non-
parametric data. Proportions were compared using Fisher’s exact
test.
RESULTS
We collected data on 306 invasively ventilated ICU patients;
of these, 282 were admitted to ICU for 48 h or more.
VARTI developed in 32 (11.3%) patients (one patient developed
two episodes of VARTI), a median period of nine (IQR
5–14) days after intubation and initiation of mechanical
ventilation. There were no significant differences in baseline
characteristics between patients developing VARTI vs. other
patients (Table 3). The commonest features present when
antibiotics were commenced were: abnormal white cell count
TABLE 3 | Baseline characteristics of patients ventilated for 48 h or more.
Patients developing Other patients ventilated 48h All
VARTI (n = 32) or more (n = 219)
PATIENTS VENTILATED FOR 48H OR MORE—BOTH STUDY PERIODS (n = 251)
Age (years), mean (± SD) 64.7 (± 15.1) 59.7 (± 16.5) 60.4 (± 16.4) p = 0.107
Sex 59.3% male 55.5% male 55.3% male p = 0.703
Median intubation day at onset of VARTI (IQR) 9 (5–14) – –
Patients developing Other patients ventilated for 48h All
VARTI (n = 15) or more (n = 98)
PATIENTS VENTILATED FOR 48 H OR MORE—SECOND STUDY PERIOD ONLY (n = 113)
BMI, mean (± SD) 25.8 ± 3.5 26.7 ± 5.9 26.6 ± 0.5.7 p = 0.449
Underlying severe respiratory failure 1/15 (6.7%) 7/98 (7.1%) 8/113 (7.1%) p = 0.945
Nature of surgery Non-surgical 14/15 (93.3%) Non-surgical 73/98 (74.4%) Non-surgical 87/113 p = 0.106
Emergency surgical 1/15 Emergency surgical 16/98 Emergency surgical 17/113
Elective surgical 0 Elective surgical 9/98 Elective surgical 9/113
Primary reason for admission “Respiratory” 8/15 (53.3%) 33/98 (33.7%) 41/113 (36.3%) p = 0.152
APACHE II score, mean (± SD) 18.3 ± 6.5 16.2 ± 7.4 16.5 ± 7.3 p = 0.275
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TABLE 4 | Clinical and radiological features present at initiation of
antibiotics for suspected VARTI.
First study Second study Combined
period (n = 17) period (n = 16) (n = 33)
Abnormal white cell count 6 10 16
Abundant and/or purulent
sputum
6 9 15
Abnormal temperature
(<36.5 or >38.0)
1 11 12
Chest x-ray signs 8 4 12
“Deterioration in gas
exchange”
3 5 8
Signs on auscultation 0 3 3
Cough 1 1 2
and offensive and/or purulent sputum (48 and 45%, episodes,
respectively), whereas deterioration in gas exchange was
relatively uncommon (24% episodes; Table 4).
Among those with VARTI, only 10 episodes met the HELICS
definition for VAP (Figure 2 and Table 5). The total number
of intubation days (for ventilated patients admitted to ICU for
48 h or more) was 2381, giving a VAP rate of 4.2 per 1000
intubation days. In total 3.5% of all patients admitted to ICU
for 48 h or more developed a HELICS-defined VAP. Six of the 10
HELICS-defined cases of VAP were “PN1,” i.e., on the basis of a
minimally-contaminated invasive respiratory sample (e.g., BAL;
Table 6). The main reasons that episodes of VARTI failed to meet
HELICS definitions are presented in Table 7. Most strikingly,
in 16 (48.4%) cases, chest radiography was not performed on
the day antibiotics were prescribed for new onset respiratory
FIGURE 2 | Flowchart demonstrating numbers of patients with suspected ICU-acquired respiratory tract infection.
Frontiers in Microbiology | www.frontiersin.org 5 August 2016 | Volume 7 | Article 1271
Pugh et al. Ventilator-Associated Pneumonia Surveillance
TABLE 5 | mCPIS and microbiological characteristics of episodes of
VARTI.
HELICS definition met HELICS definition
met (n = 10) not met (n = 23)
Mean mCPIS (± SD) 6.5 (± 1.72) 3.8 (± 1.51)*
Positive respiratory
microbiology (22/33
episodes)
– 7 out of 10 episodes:
– Enterococcus sp. (n = 2)
Enterobacter sp. (n = 1)
– Staphylococcus aureus
(flucloxacillin sensitive)
(n = 1)
– Klebsiella sp. (n = 1)
– Candida sp. (n = 2)
– “Other Gram-negative
organism” (n = 1)
– 15 out of 23 episodes:
– Enterobacter sp. (n = 1)
– Enterococcus sp. (n = 1)
– Escherichia coli (n = 1)
– Klebsiella sp. (n = 4)
– Staphylococcus aureus
– (flucloxacillin sensitive)
(n = 2)
– Pseudomonas sp. (n = 1)
– Stenotrophomonas
maltophilia (n = 1)
– Candida sp. (n = 3)
– mixed growth (n = 1)
*p = 0.01.
TABLE 6 | PN classification of HELICS-defined episodes of VAP (HELICS,
2004) and “non-HELICS” episodes referred to as “PN 0”*.
Classification Number of Organism Mean
of episode episodes mCPIS
“PN0” 6 Candida sp. 4.2
Enterobacter sp.
Klebsiella sp.
“Other Gram-negative organism”
Mixed growth
PN1 6 Staphylococcus sp. 6.7
Candida sp.
“Other Gram-negative organism”
Mixed growth
PN2 1 Enterococcus sp. 4.0
PN3 0
PN4 0
PN5 3 By definition none identified 7.0
*“PN 0,” Chest radiography not performed at time of initiation of antibiotic therapy
for suspected respiratory-tract infection onset 48 h or more after onset ventilation,
together with [two of: diagnostic signs (temperature, abnormal white cell count) OR
symptoms (sputum, cough dyspnoea, chest signs, worse gas exchange)] AND (positive
microbiology);
PN 1, Bacteriologic diagnosis on basis of quantitative analysis of minimally contaminated
lower respiratory tract specimen (e.g., broncho-alveolar lavage);
PN 2, Bacteriologic diagnosis on basis of quantitative culture from possibly contaminated
lower respiratory tract specimen (e.g., endotracheal aspirate);
PN 3, Alternative microbiological diagnosis (e.g., blood culture, culture of pleural fluid);
PN 4, Positive sputum culture or non-quantitative lower respiratory tract specimen culture;
PN 5, No positive microbiology.
tract infection precluding diagnosis according to HELICS
definition.
Of the 10 HELICS-defined cases of VAP, seven had mCPIS
of six or more (suggesting high probability of pneumonia). In
the 23 episodes in which HELICS criteria were not fulfilled
only two had a mCPIS score of six or more; mean mCPIS
was significantly lower among this cohort of patients [3.8 vs.
TABLE 7 | Reasons that episodes of VARTI did not meet HELICS definition
(HELICS definition not met in 23 out of 33 VARTI episodes).
Criteria Not met
Chest x-ray not performed 16
Chest x-ray performed but did not indicate new infiltrates 5
Lack of systemic signs 8
Lack of pulmonary signs 6
Lack of microbiological evidence 6
TABLE 8 | Baseline characteristics of patients who did and did not
develop VAC.
Patients ventilated for
minimum 48 h who
develop VAC (n = 4)
Patients ventilated
for minimum 48 h
who not develop VAC
(n = 109)
Age, mean (± SD) 57.5 ± 15.6 59.1 ± 17.5
Sex 50% male 57.1% male
BMI, mean (± SD) 35.3 26.2*
Presence of underlying
severe respiratory disease
1 (25%) 7 (6.4%)
Nature of surgery 3 (75%) Non-surgical 84 (77%) Non-surgical
1 Emergency/urgent
surgical
16 Emergency/urgent
surgical
8 Elective/scheduled
surgical
Median intubation day at
VAC onset (IQR)
6 (3.8–13.5) –
Respiratory cause of
primary reason for
admission
1/4 (25%) 40/109 (36.7%)
APACHE II, mean (± SD) 22.5 ± 17.1 16.3 ± 6.7
*Data missing in four cases.
6.5 (p = 0.01); Table 5], though positive microbiology was
subsequently identified in approximately two-thirds of cases.
In six of these 23 non-HELICS episodes, there were two or
more signs and symptoms suggestive of pneumonia as well as
subsequent positive microbiology in the absence of chest x-
ray examination, we have referred to these episodes as “PN0”
(Table 6).
Applying new CDC NHSN criteria, we identified four cases
of ventilator-associated complication (VAC) among the 113
patients ventilated for 48 h or more in the second cohort:
three on the basis of as a result of sustained increase in PEEP
application and one because of sustained increase in inspired
oxygen concentration (Table 8). In none of these cases could an
episode of VAC be further sub-classified as an IVAC. There was
no overlap between cases of VARTI and VAC (see Euler diagram,
Figure 3).
With regards to clinical outcomes (measured only in this
second stage), initiation of antibiotic therapy for VARTI 48 h
or more after onset of mechanical ventilation was associated
with significantly prolonged mechanical ventilation and ICU stay
[median 16.0 vs. 8.0 days (p = 0.01) and 25.0 vs. 11.0 days
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FIGURE 3 | Euler diagram illustrating episodes of VARTI, HELICS VAP, and VAC.
TABLE 9 | Outcomes: durations of mechanical ventilation and ICU length of stay, according to ICU-acquired respiratory morbidity.
Respiratory morbidity Duration of mechanical ventilation among sub-groups (days)
Present Absent All
VARTI Median (IQR) 16.0 (9–49) 8.0 (3.0–18.3) p = 0.01 9.0 (3.0–19.0)
HELICS-defined VAP Median (IQR) 13.5 (9.75–17.25) 9.0 (3.0–20.0)
“PN 0” VAP Median 40.5 –
VAC Median (IQR) 15.5 (8.25–28.75) 9.0 (3.0–19.5)
Respiratory morbidity Duration of ICU stay among patient sub-groups (days)
Present Absent All
VARTI Median (IQR) 25.0 (11.0–49.0) 11.0 (4.0–26.5) p = 0.01 12.4 (5.6–27.6)
HELICS-defined VAP Median (IQR) 18.5 (10.0–25.5) 11.5 (5.0–28.0)
“PN 0” VAP Median 48.5 –
VAC Median (IQR) 15.5 (7.75–36.0) 12.5 (5.0–28.0)
(p= 0.01), respectively], though not a significant increase in ICU
or hospital mortality (Tables 9, 10). Sample sizes were too small
to compare outcome data between patients who did and did not
develop VAP or VAC.
DISCUSSION
This study sheds significant light on the diagnostic processes
undertaken by ICU clinicians in Wales prior to commencing
antibiotics for suspected VARTI and provides new insight into
the utility of the currently adopted HELICS criteria used for
surveillance.
Our study investigated 282 invasively ventilated patients
admitted to ICU for 48 h or more, and in this group antibiotics
were commenced for suspected VARTI in 32 (11.3%) patients.
The most common clinical features present when clinicians
commenced antibiotic therapy were abnormal white cell count
and abundant and/or purulent sputum, rather than deterioration
in gas exchange which has been the focus of new CDC
NHSN surveillance methods. Initiation of antibiotic therapy for
suspected VARTI was associated with an approximate doubling
of duration of mechanical ventilation and ICU stay.
There were 10 episodes of VAP according to HELICS
definitions, equating to 4.2 episodes per 1000 intubation days.
Appreciating the relatively small scale of the study, that a
“Hawthorne effect” may have influenced the reporting practices
of clinical staff, and that inter-rater variation in the interpretation
of data will inevitably lead to variation in reported incidence
(Thomas et al., 2011; Stevens et al., 2014), the VAP incidence
reported during this period of enhanced surveillance is closer to
the incidence reported by colleagues in Scottish and European
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TABLE 10 | Outcomes: survival to ICU and hospital discharge, according
to ICU-acquired respiratory morbidity.
Respiratory
morbidity
ICU survival among patient sub-groups
Present Absent All
VARTI 12/15 (80%) 70/98 (68.4%) p = 0.45 82/113 (72.6%)
HELICS-defined
VAP
3/4 (75%) 79/109 (72.5%)
“PN 0” VAP 1/2 (50%) –
VAC 1/4 (25%) 81/109 (74.3%)
Respiratory
morbidity
Hospital survival among patient sub-groups
Present Absent All
VARTI 12/15 (80%) 67/ 98 (68.4%) p = 0.265 79/113 (69.9%)
HELICS-defined
VAP
3/4 (75%) 75/109 (68.8%)
“PN 0” VAP 1/2 (50%) –
VAC 1/4 (25%) 76/109 (69.7%)
centers than previous Welsh surveillance program estimates.
It seems possible that episodes of VAP have been historically
under-reported in Wales.
The most striking finding of our study is the lack of consistent
approach to chest radiography, though. Clinicians did not
perform chest radiography in nearly half of the cases treated for
suspected VARTI, and this is important since chest radiography
is used to define VAP for purposes of clinical therapy as well
as for surveillance. Antibiotic stewardship principles indicate
that the minimum effective duration of antibiotic therapy
should be used (Kollef and Micek, 2012). If ventilator-associated
tracheobronchitis (VAT) is to be treated with antibiotic therapy—
and recent evidence seems to suggest that this may prevent
progression to VAP and improve clinical outcomes (Nseir et al.,
2005, 2008, 2014; Shahin et al., 2013; Martin-Loeches et al.,
2015)—clinical resolution may occur earlier with treatment of
VAT than with VAP (Martin-Loeches et al., 2015). The distinction
between episodes of VARTI with and without radiographic
evidence of consolidation (i.e., between episodes of VAP and
VAT) is therefore likely to be important clinically.
However, for surveillance purposes (according to HELIS),
chest radiography features are essential for defining an episode
of VAP. Given the variability in chest x-ray performance, it
is perhaps unsurprising that HELICS-defined episodes of VAP
represented less than one-third of cases of the total actually
treated for VARTIs in our study. Subjectivity and inter-observer
variability with respect to chest radiography interpretation have
been highlighted as a potential contribution to differences
in reported VAP rates in the US (Klompas, 2012) but we
are unaware of previous reports which describe the non-
performance of chest radiography as being such a potentially
important confounder of surveillance data.
In the US, attempts to focus on “hard” objective data
and to exclude more subjective elements (including chest
radiography; Klompas, 2010) recently led to complete revision
of ICU surveillance methodology and the introduction of the
concept of a “Ventilator-Associated Event,” defined on the basis
of a deterioration in oxygenation as a “Ventilator-Associated
Complication” or “VAC” (Magill et al., 2013). An episode of
VAC correlates with poorer clinical outcome (Klompas et al.,
2011), but a number of authors have observed that such episodes
represent a heterogeneous group of pulmonary conditions
which include VAP but also atelectasis, pulmonary edema, and
thrombo-embolism (Lilly et al., 2014; Stoeppel et al., 2014;
Bouadma et al., 2015; Chang et al., 2015). In our cohort, only
a very small number of cases of VAC were identified. Mortality
was high in the group of patients with VAC but we found no
overlap with our VARTI cohort. Deterioration in oxygenation
does not appear to be a frequent reason for commencing
antibiotic therapy in our patients. Furthermore, in ICUs
which predominantly use paper-based rather than electronic
patient records, daily collection of data for VAC analysis was
reported by our data collectors to be rather difficult and
time-consuming.
We calculated a modified CPIS when antibiotics were
commenced for suspected respiratory tract infection as an index
of the probability of pneumonia. A mCPIS of six or greater was
significantly more likely to occur with HELICS-defined episodes
of VAP and for other episodes of RTI. However, as chest x-ray
features contribute up to two points to this score, and are also
an essential criterion for HELICS-confirmed episode, this is an
expected association.Without reducing the variability with which
chest radiography is performed, CPIS is unlikely to provide a
reliable tool for our surveillance program.
Initiation of antibiotic therapy for suspected VARTI was
associated with a significant increase in duration of mechanical
ventilation and ICU stay. Among this group of patients were
those with HELICS-defined episodes of VAP, for whom longer
durations of ventilation and ICU stay are consistent with
previous work (Safdar et al., 2005; Bekaert et al., 2011; Melsen
et al., 2013; Muscedere et al., 2013). However, among this
group were also cases in which there was positive respiratory
microbiology and two or more diagnostic signs or symptoms
of pneumonia, but in whom chest radiography had not been
performed. Not having met established HELICS definitions, we
have referred to these as “PN0” episodes (Tables 6, 9, 10).
Our present limited data suggests that these patients also have
relatively prolonged duration of mechanical ventilation and
ICU stay and suggests to us that the application of HELICS
surveillance definition is failing to detect episodes of VARTI with
appreciable morbidity.
Our study has a number of limitations. Firstly, data collection
was restricted to two 14-day periods. Infectious episodes
occurring outside the primary data collection period may have
been missed, and as a result we may have under-estimated the
number of infections occurring on a per patient basis, rather
than per intubation days. Despite this, our estimate of VARTI
(11.3%) correlates very closely with estimates from a previous
UK antimicrobial point prevalence study (12%; Coello et al.,
2011). Secondly, with the exception of the VAE data during
the latter phase of the study, data collection was triggered
by initiation of antibiotic therapy. Significant respiratory tract
infection could have been present, but our ability to capture an
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episode relied on the clinical team initiating treatment. However,
using the initiation of antibiotics to trigger ICU surveillance
data capture has previously been described (Kaiser et al., 2014)
and is recognized in the VAE surveillance methodology as an
unambiguous factor within the definition of an “I-VAC.” Amajor
strength of our study is that all acute ICUs in Wales contributed
and we believe our findings accurately reflect current intensive
care practice.
CONCLUSIONS
Our data suggest that established measurements of VAP rates in
Wales have unfortunately under-estimated the true incidence of
VAP. The higher rate suggested by our enhanced surveillance
study is more in keeping with rates published for comparable
geographical regions. However, even this higher rate may
underestimate the true incidence given the marked variability in
performance of chest x-ray at time of diagnosis of respiratory
tract infection. The absence of radiographic data is a limitation
to a surveillance mechanism which uses the HELICS definition of
VAP. This is a novel finding and a concern which may be relevant
outside our country.
Ensuring a mechanism for identifying the wider burden of
VARTI in Wales while enabling us to contribute to a Europe-
wide surveillance programme will be a challenge, particularly
in the context of current diagnostic practices. The use of
mCPIS for surveillance is hampered by inconsistent radiographic
performance and our study indicates that mCPIS could not
reliably replace the HELICS definition of VAP. Our results
also confirm that adopting the CSC NHSN VAE surveillance
methodology in Wales may not provide a solution. The low
degree of agreement between episodes of clinician-perceived
respiratory tract infection and episodes of VAC among our
patient population—as well as logistical problems of data
collection in “paper based” ICUs—raises doubt over the
suitability of this methodology in Wales at present. However,
a sensible step may be the further characterization of episodes
of VARTI—diagnosed according to clinical and microbiological
features, but without the benefit of radiographic data. This
approach including the “PN0” definition is being piloted in the
Welsh ICUs and the validity of this approach should be subject to
further collaborative study.
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